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a  b  s  t  r  a  c  t
Acute  lymphoblastic  leukemia  (ALL)  is  an aggressive  cancer  that  occurs  in  both  children  and  adults.
Starting  from  an  integrated  analysis  of miRNA/mRNA  expression  proﬁles  in 20 ALL  patients,  we  identify  a
negative  correlation  between  miR-181a  and  EGR1.  Coherently,  miR-181a  over-expression  in  Jurkat  T-ALL
cells decreases  EGR1  expression,  increasing  cell  proliferation  and enhancing  the  cell-cycle  progression
from  G1 to S  phase.  We  show  that  EGR1  is  a new  direct  target  of miR-181a.  Our  ﬁndings  suggest  that
miR-181a  behaves  as an  onco-miRNA  in  ALL  by  down-regulating  EGR1.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
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. Introduction
Acute lymphoblastic leukemia (ALL) is a malignant neoplasm
hat affects both adults and children. It is the most common pedi-
tric hematologic tumor, representing over a quarter of all pediatric
ancers [1–3]. Several cytogenetic abnormalities have been identi-
ed as one of the causes of ALL, in particular associated with distinct
mmunologic phenotype and treatment outcome [4–6]. Moreover,
t has been shown that also epigenetic factors, as DNA methyla-
ion and chromatin remodeling, are strongly involved in etiology
f ALL [7,8]. Several studies have highlighted MicroRNAs (miR-
As) expression deregulation in ALL [9–11]. miRNA are a class of
on-coding, single stranded RNAs composed of approximately 22
ucleotides, acting as negative regulators of gene expression at the
ost-transcriptional level. They are able to recognize their target
RNAs by imperfect base pairing with 3′-untranslated region (3′-
TR) [12]. The interaction between a miRNA and its target results in
he inhibition of translation and/or destabilization of target mRNA
olecules [13]. miR-181a is known to play an important regulatory
∗ Corresponding author at: Dipartimento di Biotecnologie Cellulari ed Ematologia,
Sapienza” Università di Roma. Policlinico Umberto I, V Clinica Medica, V.le Regina
lena, 324, 00161 Roma, Italy. Tel.: +39 064457731.
E-mail address: valerio.fulci@uniroma1.it (V. Fulci).
ttp://dx.doi.org/10.1016/j.leukres.2015.01.010
145-2126/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article unrole in leukocyte cell differentiation and function [14]. It has been
shown that miR-181a has a key role in T-cell maturation. Partic-
ularly, miR-181a is speciﬁcally enriched at the CD4+CD8+ stage of
thymocyte development, and it is able to inhibit the expression of
genes involved in positive selection and T-cell maturation such as
BCL2, CD69, and TCR [15]. miR-181a acts also as a “rheostat” during
T-cell development, governing T-cell sensitivity and selection [16].
Furthermore, aberrant expression of miR-181a has been
reported in several types of cancer, for instance in non-small-cell
lung cancer [17], breast cancer [18], hepatocellular carcinoma [19],
gastric and colon cancer [20,21], glioma [22] and oral squamous
cell carcinoma [23].
In this work, we identify EGR1 as a miR-181a target. The early
growth response gene 1 (EGR1) is a member of the early growth
response (Egr) family of genes encoding for zinc-ﬁnger transcrip-
tion factors [24]. EGR1 has a dual nature: it can act both as an
oncogene or a tumor suppressor. It is oncogenic in prostate and
gastric cancer [25,26], but it has tumor suppressor properties
in different human tumors including non-small-cell lung cancer
[27] and breast cancer [28]. It is known that EGR1 abrogates
the E2F1 block in terminal myeloid differentiation suppressing
its leukemia-promoting function. EGR1 promotes G0/G1 cell-cycle
arrest behaving like a tumor suppressor gene [29].
EGR1 has been identiﬁed by us as a putative miR-181a target
by two different approaches. First, we have used a novel analytical
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ethod to combine miRNA and gene expression proﬁles from a
eries of adult ALL patients [30], secondly, we analyzed the whole-
ranscript expression proﬁling of Jurkat cells (T-ALL cell line) over-
xpressing miR-181a using a microarray.
We  demonstrate that miR-181a strongly reduces EGR1 expres-
ion, and enhances the proliferation of Jurkat T cells. Our study
hows that miR-181a acts as an onco-miRNA in T-ALL cells reg-
lating the expression of tumour suppressor gene EGR1. For the
rst time, EGR1 is shown to be a miR-181a target, opening new
erspectives in cancer therapies.
. Materials and methods
.1. Cell and culture conditions
Jurkat cells were purchased from Deutsche Sammlung von
ikroorganismen und Zellkulturen (DSMZ) and cultured in RPMI-
640 Medium (SIGMA) supplemented with 10% fetal bovine serum
SIGMA), at 37 ◦C in a 5% CO2 atmosphere.
.2. Construction of a lentiviral vector expressing miR-181a
PGK-miR181a expression construct was obtained amplify-
ng a region of about 200 nt containing miR-181a precursor,
rom human genomic DNA. We  used the following primers
esigned to incorporate RsrI and NheI restriction sites and
 bp of extra random sequence to aid in restriction diges-
ion: 5′-GCGCGCCGGACCGAAGTGAGTAGAATTCTGAGTTTTGAGG-
′ (forward), 5′-GCGCGCGCTAGCTGTCTTCAGCGAATTCTGAGC-3′
reverse). The ampliﬁed region was cloned into the RsrI NheI sites of
1074.1071.hPGK.GFP.WPRE.mhCMV.dNGFR.SV40PA (kindly pro-
ided by Prof. Luigi Naldini). PGK-control was obtained by
ubstituting miR-181a precursor fragment (RsrI–NheI) with a
equence encoding for an hairpin yielding a 22-mer RNA designed
o lack homology to any human gene. The lentiviral vector express-
ng miR-181a and the packing vectors pLP1, pLP2, and pLP/VSVG
ere co-transfected into HEK293T cells, and culture medium was
ollected at 48 h. The medium was ﬁltered through 0.45-m pore
itrocellulose ﬁlters and then centrifuged in a Beckman ultracen-
rifuge (Beckman, OptimaTM LE-80K) at 25,000 rpm for 2 h at 4 ◦C.
he precipitate was re-suspended in RPMI complete medium. The
iral supernatant and Polybrene 8 g/ml were added to the Jurkat
ells.
.3. Generation of Jurkat-miR-181a + EGR1 cell lines
The lentiviral vector expressing EGR1 (pLenti-GIII-UbC-Human-
GR1 Lentiviral Vector; abm) and the packing vectors pLP1, pLP2,
LP/VSVG were co-transfected into HEK293T cells, and culture
edium was collected at 48 h. Blank vector (pLenti-UbC-Blank
ector; abm) was used as negative control in place of the vec-
or expressing EGR1. The medium was ﬁltered and centrifuged as
escribed above. The precipitate was re-suspended in RPMI com-
lete medium. The viral supernatant and Polybrene 8 g/ml were
dded to the Jurkat-Control cell lines or Jurkat-miR-181a cell line.
.4. Microarray data preprocessing
Three biological replicates for each sample were hybridized on
he array (Human 1.0 ST microarrays, Affymetrix, Santa Clara, CA).
ffymetrix. “CEL” ﬁles were separately processed for each replicate
nd experimental condition using the Robust Multi-array Average
RMA) procedure with quantile normalization, log2 transformation
nd background subtraction, as implemented in the Bioconductor
ackage “oligo”. Then, as implemented in the R package “gene-
lter”, a generic ﬁlter was applied to the normalized expressionarch 39 (2015) 479–485
values as follows: (I) remove Affymetrix control probesets; (II)
remove probesets marked by low or null expression in total RNA
samples (i.e.: require expression value > log2(100) in both miR-
181a over-expressing samples and control samples; (III) remove
probe sets lacking annotation to a gene symbol. Therefore, we
ended up with a list of 6300 ﬁltered probesets. The “limma”
package from BioConductor open source software for bioinformat-
ics (under R statistical software) was  used to calculate moderated
t-statistics (based on the empirical Bayes approach) to identify dif-
ferentially expressed genes between the miR-181 over-expressing
group and control group. This led to the identiﬁcation of differen-
tially expressed genes between the two experimental conditions.
Because of multiple hypothesis testing, p values were adjusted by
the Benjamini-Hochberg false discovery rate (FDR) method. This led
to the detection of a top list of two differentially expressed genes
with and adjusted p-value under the 0.05 threshold.
2.5. RNA isolation, reverse transcription (RT), and quantitative
real-time PCR (qPCR)
The total RNA was isolated from cells using Trizol (Invi-
trogen Life Technologies). Reverse transcription and quantita-
tive real-time PCR of mature miR-181a and small nucleolar
RNA U44 normalization control were performed as described
[31,32] with minor changes. Brieﬂy, 500 ng of total RNA was
reverse transcripted by Enhanced Avian Reverse Transcriptase
(Sigma), using the following primers: miR-181a RT primer 5′-
AGGTCGTCGGTATTGCTGACTCACCGAC -3′; RNAU44 reverse primer
5′-GTCAGTTAGAGCTAATTAAGA-3′. Quantitative PCR (qPCR) was
performed by SensiMixTM SYBR & Fluorescein Kit (Bioline). The
level of mature miR-181a expression was normalized to those of
internal control (RNAU44). Mature miRNAs were quantiﬁed with
the standard curve method.
Oligonucleotides used for qPCR of human mature miRNA-
181a and RNAU44 were: miR-181a forward 5′AA+A+T+
AACGCTGTC-3′ (nucleotides preceded by ‘+’ are LNA modiﬁed),
reverse 5′-AGGTCGTCGGTATTGCTG-3′; RNAU44 forward 5′-
CCTGGATGATGATAAGCAATG-3′, reverse 5′-GTCAGTTAGAGCTAA-
TTAAGA-3′. Abundance of EGR1 and EGR1 target genes mRNA
were determined by RT-qPCR, using GAPDH as normalizing gene,
according to the manufacturer’s instructions (SensiMixTM SYBR &
Fluorescein Kit (Bioline)). Oligonucleotides used for RT-qPCR of
human mRNA were: EGR1 forward 5′-AGCCCTACGAGCACCTGAC-
3′, reverse 5′-GGTTTGGCTGGGGTAACTG-3′; TGF1 forward
5′-ACTACTACGCCAAGGAGGTCAC-3′, reverse 5′-TGCTTGAACTTGT-
CATAGATTTCG-3′; PTEN forward 5′-GCACAAGAGGCCCTAGATTTC-
3′; reverse 5′-CGCCTCTGACTGGGAATAGT-3′; BCL2 forward
5′-AGTACCTGAACCGGCACCT-3′; reverse 5′-GCCGTACAGTTCCAC-
AAAGG-3′; p53 forward 5′-GGGGTGACCTGGAGACCTAC-3′, reverse
5′-AGGAGAAGTGGGGCACCT-3′; p73 forward 5′-CTGGAGCTGAT-
GGAGTTGG-3′, reverse 5′-ACGGGGGCTGTAGGTGAC-3′; Fibronec-
tin forward 5′-CTGGCCGAAAATACATTGTAAA-3′, reverse 5′-
CCACAGTCGGGTCAGGAG-3′; Gapdh: forward 5′-GAAATCCC-
ATCACCATCTTCCAGG-3′, reverse 5′-GAGCCCCAGCCTTCTCCATG-3′.
2.6. Western blot analysis
Samples of 1 × 106 cells were washed with ice-cold PBS buffer
and lysed with Ripa Lysis Buffer. Proteins (30 g/lane) were
separated on 10% SDS-polyacrylamide gels and transferred to
nitrocellulose membranes. Immunoblots were probed with the
following primary antibodies: anti-EGR1 (1:500 Cell Signaling),
and anti-GAPDH (1:20,000 Cell Signaling). Signals were revealed
after incubation with recommended secondary antibody coupled
to peroxidase using chemiluminescent HRP substrate reagent
(Thermo Scientiﬁc).
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.7. Construction of plasmid EGR1 3′-UTR
Human genomic DNA was isolated and puriﬁed from Jurkat
ith DNesy® Blood and Tissue Kit according to the manufac-
urer’s protocol. The 3′-untranslated region (UTR) sequence of EGR1
as PCR ampliﬁed from the genomic DNA using the following
rimers: forward 5′-GCGCGCTCTAGACTTCCCTTCCTCAGCTGTCA-3′
nd reverse 5′-GCGCGCTCTAGATATCCCATGGGCAATAAAGC-3′. The
rimers were designed incorporating XbaI restriction site and 4 bp
f extra random sequence to aid in restriction digestion. XbaI-
igested PCR products were cloned into a XbaI-digested pGL3 dual
uciferase reporter vector (Promega). The mutated version EGR1 3′-
TR mut, was generated utilizing the EGR1 3′-UTR plasmid as
emplate and modifying the miR-181a seed binding site using the
uikChange II XL site-directed mutagenesis kit (Agilent Technolo-
ies).
The mutagenic primers used were: forward 5′-
TATAAATATATTCAGGAGTTGGTTGTAGTTACCTACTGAGTAGGC-3′
nd reverse 5′-GCCTACTCAGTAGGTAACTACAACCAACTCCTGAA-
ATATTTATAA-3′.
.8. Dual luciferase assays
For luciferase assays, HEK293T cells were seeded onto 24-
ell plate (1 × 106 cells each well) the day before transfection.
00 ng of pGL3-ﬁreﬂy-EGR1 3′-UTR and 300 ng of pCMV-miR-181a
ORIGENE) or pCMV-control were co-transfected into HEK293T
ells. Ten ng of pRL-TKRenilla were included as internal control.
he same assay was performed using pGL3-ﬁreﬂy-EGR1 3′-UTR-
ut  instead of pGL3-ﬁreﬂy-EGR1 3′-UTR. Forty-eight hours later,
uciferase activity was detected by Dual-Luciferase Reporter Assay
ystem (Promega) according to the manufacturer’s instructions.
ireﬂy luciferase activity was normalized to Renilla activity for each
ransfected well.
.9. Cell proliferation assay
Cell proliferation was determined by cell counting and CellTiter
6 AQueous assay (Promega). In cell counting, 105 cells were seeded
n 12-well plates in duplicate and grown for 72 h. Cell counting was
erformed after 24, 48 and 72 h. Cell titer 96 AQueous assay was
erformed according to the manufacturer’s recommendations.
ig. 1. Identiﬁcation of putative miR-181a targets. (A) The graph shows the negative co
nalyzed (Pearson correlation (r) = −0.66). (B) The graph displays genes expression mod
eplicates. EGR1 is indicated by the black arrow.arch 39 (2015) 479–485 481
2.10. Cell-cycle analysis
106 cells were ﬁxed in cold ethanol, washed, resuspended in
phosphate-buffered saline containing 50 g/ml propidium iodide
(PI) and 50 g/ml RNAase A, and analyzed by ﬂow cytometry on a
FACScan (Becton Dickinson).
2.11. Apoptotic assay
104 cells were seeded in 96-well plates in triplicate and apop-
totic cells were determined using the Caspase-Glo3/7 assay system
(Promega) according to the manufacturer’s recommendations.
2.12. Statistical analysis
Data were analyzed using GraphPad Prism (GraphPad Software,
San Diego, CA). Statistical differences were determined by paired
t test, with values of p < 0.05 considered statistically signiﬁcant.
Results were expressed as mean ± S.E.M. of at least three indepen-
dent experiments.
3. Results
3.1. Identiﬁcation of putative targets by integrated analysis of
miRNA and mRNA expression proﬁles
The involvement of different miRNAs in a series of adult ALL
cases was  explored in our previous work [30] using a novel analyt-
ical method to combine miRNA and gene expression proﬁles. We
identiﬁed miRNA/mRNA pairs with positive and negative expres-
sion correlation as deﬁned in [30]. Focusing our attention on pairs
displaying the lowest negative correlation scores, we decided to
investigate the nature of the correlation between miR-181a and
EGR1. Fig. 1A shows the negative correlation between the miR-181a
expression and the expression of its putative target EGR1 in each
of the 20 ALL cases analyzed (Pearson correlation (r) = −0.66).
3.2. Identiﬁcation of miR-181a targets by gene expression
analysisJurkat cells, a well-known immortalized line of human T-ALL,
have been used as in vitro model in our study. Since miR-181a
expression level in Jurkat cells is quite low (data not shown), they
rrelation between miR-181a and its putative target EGR1 in each of 20 ALL cases
ulation in response to miR-181a over-expression, in three independent biological
482 L. Verduci et al. / Leukemia Research 39 (2015) 479–485
Fig. 2. miR-181a down-regulates EGR1 by directly binding its 3′-UTR. miR-181a (A) and EGR1 mRNA expression (B) were detected by RT-qPCR in Jurkat-miR-181a cell line
and  in Jurkat-Control cell line. Overexpression of miR-181a signiﬁcantly down-regulates mRNA expression of EGR1. (C) Western blot assays show that overexpression of
miR-181a reduces the EGR1 protein expression. GAPDH was  used as internal loading control. Top, a representative of the Western blot. Bottom, densitometric quantiﬁcation
of  three independent experiments performed as described above. Band intensity was normalized to that of GAPDH. (D) Dual luciferase assays show that miR-181a reduces
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CMV-miR-181a precursor or control plasmid PCMV. The negative control (EGR1 3
esults  in all ﬁgures were presented as mean ± SEM from three independent experi
epresent a good cell model to over-express miR-181a and to ana-
yze the resulting phenotype. For this purpose, we generated a
iR-181a lentiviral-based expression vector (pRRL-miR-181a) and
ransduced it in Jurkat cells. To assess the speciﬁcity of miR-181a
ffects, we used as control a lentiviral construct (pRRl-ct), encod-
ng for a hairpin RNA designed to lack homology to any human
ene. After performing lentiviral infections, the over-expression of
ature miR-181a has been conﬁrmed by mature miRNA-speciﬁc
T-qPCR. Fig. 2A shows that overexpression of miR-181a results
n a 2-fold increase in Jurkat-miR-181a cell lines compared to
urkat-Control cell lines (Fig. 2A). After the generation of the Jurkat-
iR-181a cell line, we compared the mRNA expression proﬁle of
iR-181a overexpressing cell line with the one of the control cell
ine, in three independent biological replicas. In particular, the Gene
hip Human Gene 2.0 ST Array (Afﬁmetrix) has been used. The
catter plot in Fig. 1B shows the genes modulated in consequence of
iR-181a over-expression. Among the most statistically signiﬁcant
odulated genes, we focused on miR-181a putative target genes
redicted by two different microRNA databases such as TargetScan
nd miRanda. EGR1 has been found to be the most modulated target
f miR-181a, as indicated in Fig. 1B. These results are in line with
ur original analysis [30] suggesting EGR1 as a miR-181a target..3. EGR1 is a target of miR-181a
In order to conﬁrm that EGR1 is a target of miR-181a, we eval-
ated the expression level of EGR1 mRNA by RT-qPCR and ofR1 3′-UTR and mutant (mut) 3′-UTR regions were obtained by co-transfection of
 with PCMV) was  set as 100%. Fireﬂy activity was normalized to that of Renilla. The
 (*p  < 0.05; **p < 0.01; ***p < 0.001 (paired t-test)).
EGR1 protein by western blot analysis in Jurkat-miR-181a cell lines
versus Jurkat-Control cell lines. EGR1 mRNA and EGR1 protein level
were decreased by about 60% (Fig. 2B) and 50% (Fig. 2C), respec-
tively. To conﬁrm that miR-181a is a direct regulator of EGR1, the
3′-UTR of human EGR1 (EGR1 3′-UTR) was cloned downstream of
a luciferase coding sequence. We  performed luciferase assays in
HEK293T cell line, comparing the luciferase activity of EGR1 3′-
UTR co-transfected with a plasmid containing mir-181a precursor
(PCMV-miR-181a), against the luciferase activity of EGR1 3′-UTR
co-transfected with a control plasmid PCMV. Co-transfection with
PCMV-miR-181a causes a 33% reduction in EGR1 3′-UTR luciferase
expression (Fig. 2D). To further demonstrate the miRNA-target gene
direct interaction, we  performed a site-speciﬁc mutagenesis in the
putative miRNA binding site of the EGR1 3′-UTR sequence, and then
repeated the luciferase reporter assay. Inactivation of miR-181a
binding sites in the EGR1 3′-UTR restored luciferase expression,
indicating a direct binding of miR-181a on EGR1 3′-UTR (Fig. 2D).
3.4. Biological consequences of miR-181a over-expression in
T-acute lymphoblastic leukemia cells
Given the importance of EGR-1 in the regulation of cell-cycle
progression [29], we addressed the role of miR-181a in Jurkat
cell proliferation. Overexpression of miR-181a by lentiviral infec-
tion signiﬁcantly up-regulated the proliferation rate of Jurkat cells
detected by cell counting and also the cell viability detected by
MTS  tetrazolium assay (Fig. 3A and B). To better understand the
L. Verduci et al. / Leukemia Research 39 (2015) 479–485 483
Fig. 3. Overexpression of miR-181a in Jurkat T-cell increases cell proliferation and promotes cell-cycle progression. Cell proliferation and cell viability of Jurkat miR-181a
and  Jurkat Control cell line were detected by cell counting after 24, 48 and 72 h from seeding (A) and by MTS  tetrazolium assay after 48 h from seeding, respectively (B). Both
assays  were repeated ﬁve times on independent cell cultures. (C) Propidium iodide ﬂow cytometric assay was performed to analyze the cell cycle. In Jurkat miR-181a cell
line  we observed an increase of S phase and a decrease of G0/G1 phase in comparison to Jurkat control cell line. Cell-cycle analysis was performed in triplicate. (D) Caspase
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ix  times. The results in all ﬁgures were presented as mean ± SEM (*p < 0.05; **p < 0
egulation of Jurkat cell proliferation by miR-181a, we exam-
ned cell-cycle proﬁle. Jurkat-miR-181a cells displayed a signiﬁcant
ncrease in the number of cells in S phase and a decrease in
he number of cells in G0/G1 phase (Fig. 3C). This indicates that
verexpression of miR-181a enhances cell-cycle progression by
romoting G1 to S phase transition. We  also tested the apoptotic
ate in Jurkat-miR-181a measuring Caspase3/7 activities. We  did
ot observe any statistically signiﬁcant difference between apo-
tosis level in Jurkat-miR-181a cell line compared to Jurkat-Control
ell line (Fig. 3D).
.5. Biological effects of miR-181a over-expression are mediated
y EGR1
In order to verify that the phenotype associated with miR-181a
ver-expression in Jurkat cell is mediated by EGR1, we evalu-
ted by RT-qPCR the expression level of different EGR1 targets
enes involved in cell proliferation and cell cycle [33]. In partic-
lar, we measured the expression of TGF1, BCL2, p53, p73, PTEN
nd Fibronectin [33,35–40]. Coherently with our hypothesis, four
ut of six genes (TGF1, BCL2, p53 and p73) show a signiﬁcant
eduction of expression in miR-181a overexpressing cells. The PTEN
xpression is reduced even though its change does not attain sta-
istical signiﬁcance, while no change is observed in the Fibronectin
xpression (Fig. 4A).erence between Jurkat miR-181a and Jurkat Control cell line. Assay was performed
*p < 0.001 (paired t-test)).
To provide additional evidences that the biological effects of
miR-181a is mediated by EGR1, we  went on restoring EGR1
expression in Jurkat-miR-181a by lentiviral-based expression
vector (pLenti-GIII-UbC-Human-EGR1 Vector) and observing the
resulting phenotype. To assess the speciﬁcity of EGR1 effects,
we used as control a lentiviral construct indicated as blank
(pLenti-UbC-Blank Vector) and transduced it in Jurkat-miR-
181a and Jurkat-Control cell lines. We  obtained the three cell
lines Jurkat-miR-181a + EGR1, Jurkat-miR-181a + blank and Jurkat-
Control + blank.
The rescue of EGR1 protein in miR-181a over-expressing
cells was  conﬁrmed by western blot analysis (Fig. 4B). The
cell proliferation proﬁle of Jurkat-miR-181a + EGR1 is similar
to those of Jurkat-Control + blank cell line (Fig. 4C and D). In
detail, the cell viability of Jurkat-miR-181a + EGR1 cell line is
signiﬁcantly reduced in comparison to Jurkat-miR-181a + blank
and it is similar to those of Jurkat-Control + blank cell line
(Fig. 4C). In a coherent manner, in the cell-cycle analysis the
percentage of cells in S-phase in Jurkat-miR-181a + EGR1 is sig-
niﬁcantly reduced when compared to Jurkat-miR-181a + blank
cell line. These evidences show that the rescue of EGR1 protein
is able to revert the phenotype originally observed in Jurkat-
miR-181a cell line, demonstrating that EGR1 decrease has an
essential role in deﬁning the biological effects of miR-181a over-
expression.
484 L. Verduci et al. / Leukemia Research 39 (2015) 479–485
Fig. 4. The phenotype of miR-181a over-expression is mediated by EGR1. (A) TGF1, BCL2, p53, p73, PTEN and Fibronectin mRNA expression were detected by RT-qPCR in
Jurkat-miR-181a cell line and in Jurkat-Control cell line. (B) Western blot assays show the rescue of EGR1 protein in miR-181a over-expressing cells. GAPDH was  used as
internal loading control. Top, a representative of the Western blot. Bottom, densitometric quantiﬁcation of three independent experiments performed as described above.
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. Discussion
This work was inspired by the expression analysis of miRNA
nd mRNA proﬁles in 20 ALL patients. In order to understand
he functional regulatory effects of differential miRNAs on their
argets, we used a novel analytical method to combine their
xpression proﬁles [30]. From this analysis, we  selected the
air miR-181a/EGR1, whose negative correlation was  conﬁrmed
hereafter by in vitro experiments using Jurkat T-ALL cell line. This
ell line is notoriously difﬁcult to transfect transiently; therefore,
e performed a lentiviral infection to obtain a stable Jurkat cell
ine over-expressing miR-181a. By gene expression analysis we
btained a list of genes modulated as a consequence of miR-181a
ver-expression. Among these genes we focused on the miR-181a
argets, ﬁnding EGR1 as the most statistically signiﬁcant mod-
lated one. The phenotype of miR-181a over-expressing cells is
haracterized by the increase of cell viability and proliferation, and
y the promotion of the cell-cycle progression.
The same miRNA can have functions either as tumor suppressor
r oncogene, depending on the cellular context and on the conse-
uent expression of its targets [34]. An example of miRNA that has
uch dual behavior is the miR-181a. It is known that miR-181a acts
s a tumor suppressor in glioma [22] and in oral squamous cell
arcinoma [23], but it behaves as an onco-miRNA in non-small-cell, Jurkat miR-181a + blank and Jurkat-miR-181 + EGR1 cell line was detected by MTS
dent cell cultures. (D) Propidium iodide ﬂow cytometric assay was performed to
es were presented as mean ± SEM (*p  < 0.05;**p < 0.01; ***p < 0.001 (paired t-test)).
lung cancer [17], breast cancer [18], hepatocellular carcinoma [19]
and gastric and colon cancer [20,21]. In agreement with the latter
examples, we  observed that miR-181a has a role of onco-miRNA
in ALL.
In this work, we  show that EGR1 is a new direct target of miR-
181a. Our data suggest that EGR1 is responsible, at least in part,
for the phenotype observed in Jurkat over-expressing miR-181a.
There are instances of the EGR1 activity as oncogenes [25,26], but
also other instances where it has tumor-suppressive properties
[27–29]. In agreement with the EGR1 role in non-small-cell lung
cancer [27], breast cancer [28] and myeloid leukemia [29], our
data support the idea that EGR1 has a role of tumor suppressor
in ALL. Indeed, this is demonstrated by the analysis of expres-
sion conducted on some genes directly or indirectly subject to
EGR1 regulation. In particular, we focused on TGF1, BCL2, p53
and p73, whose transcription is promoted by EGR1 [35–40]. Ana-
lyzing the expression of such genes, we  observed a reduction in
miR-181a over-expressing cells when compared to Jurkat-Control
cell line.
To test directly the EGR1 capability of acting as tumor suppres-
sor gene in ALL, we attempted to produce a stable Jurkat cell line
down-expressing EGR1. Unfortunately, the Jurkat cells fail to sur-
vive when the expression level of EGR1 is dramatically reduced
(data not shown).
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On the contrary, Jurkat-miR-181a cells are able to survive
nd proliferate when we partially restore the EGR1 expression.
urkat-miR-181a + EGR1 cells show a reduction of cell viability
nd a decrease of cells in S-phase in comparison to Jurkat-miR-
81a + blank.
The rescue of EGR1 leads to a phenotype similar to the one of
he control cells, demonstrating that EGR1 is responsible for the
henotype observed in Jurkat over-expressing miR-181a.
In conclusion, we obtained evidences that miR-181a can act as
n onco-miRNA repressing the tumor suppressor EGR1. Our work
pens the way for a series of future studies in which the recip-
ocal expression of miR-181a and its target EGR1 may  be useful
n predicting clinical outcome in ALL. Although other studies are
ecessary to thoroughly elucidate the role of the miR-181a/EGR1
nterplay, the discovery of their functional relationship will lead to
 better understanding of molecular pathways involved in ALL, con-
ributing to open new possibilities for future diagnosis, prognosis
nd therapies in patients affected by acute leukemia.
unding
This work was supported by grants from AIRC IG 2010N.10085:
Characterization of the role of miR-103, let-7, miR-181, miR-19
nd miR-93 in Acute Lymphoblastic Leukemias.” and by FIRB grant
Nuovi marcatori per valutare suscettibilità, prognosi e possibilità
i terapie mirate nelle leucemie acute, de novo e secondarie del
ambino e dell’ adulto”.
We thank Dr. Luigi Naldini for kindly providing published
entiviral constructs.
onﬂict of interest
The authors declare no competing ﬁnancial interests.
cknowledgements
Author’s contributions: L.V., V.F., C.C. conceived and designed
he experiments; L.V., G.A., I.L. performed experiment; S.G. per-
ormed bioinformatics analysis; L.V., V.F. wrote the paper; G.M.
upervised the study.
eferences
[1] Pui CH, Evans WE.  Treatment of acute lymphoblastic leukemia. N Engl J Med
2006;354(2):166–78.
[2] Vitale A, Guarini A, Chiaretti S, Foà R. The changing scene of adult acute lym-
phoblastic leukemia. Curr Opin Oncol 2006;18(6):652–9.
[3] Pui CH. Recent research advances in childhood acute lymphoblastic leukemia.
J  Formos Med  Assoc 2010;109(11):777–87.
[4] Faderl S, Kantarjian HM,  Talpaz M,  Estrov Z. Clinical signiﬁcance of cytogenetic
abnormalities in adult acute lymphoblastic leukemia. Blood 1998;91(11):3995.
[5] Pui CH, Relling MV,  Downing JR. Acute lymphoblastic leukemia. N Engl J Med
2004;350(15):1535.
[6] Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet
2008;371(9617):1030.
[7] Nordlund J, Bäcklin CL, Wahlberg P, Busche S, Berglund EC, Eloranta ML, et al.
Genome-wide signatures of differential DNA methylation in pediatric acute
lymphoblastic leukemia. Genome Biol 2013;14(9):r105.
[8] Shi J, Whyte WA,  Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe JS, et al. Role of
SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regula-
tion. Genes Dev 2013;27(24):2648–62.
[9] Li XJ, Luo XQ, Han BW,  Duan FT, Wei  PP, Chen YQ. MicroRNA-100/99a, dereg-
ulated in acute lymphoblastic leukaemia, suppress proliferation and promote
apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways. Br J
Cancer 2013;109(8):2189–98.10] Yan J, Jiang N, Huang G, Tay JL, Lin B, Bi C, et al. Deregulated MIR335 that tar-
gets MAPK1 is implicated in poor outcome of paediatric acute lymphoblastic
leukaemia. Br J Haematol 2013;163(1):93–103.
11] Burke MJ,  Bhatla T. Epigenetic modiﬁcations in pediatric acute lymphoblastic
leukemia. Front Pediatr 2014;2:42.
[arch 39 (2015) 479–485 485
12] Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often ﬂanked by
adenosines, indicates that thousands of human genes are microRNA targets.
Cell 2005;120(1):15–20.
13] Filipowicz W,  Bhattacharyya SN, Sonenberg N. Mechanisms of post-
transcriptional regulation by microRNAs: are the answers in sight? Nat Rev
Genet 2008;9(2):102–14.
14] Sun X, Sit A, Feinberg MW.  Role of miR-181 family in regulating vascular inﬂam-
mation and immunity. Trends Cardiovasc Med  2014;24(3):105–12.
15] Neilson JR, Zheng GX, Burge CB, Sharp PA. Dynamic regulation of miRNA expres-
sion in ordered stages of cellular development. Genes Dev 2007;21(5):578–89.
16] Li QJ, Chau J, Ebert PJ, Sylvester G, Min  H, Liu G, et al. miR-181a is an intrinsic
modulator of T cell sensitivity and selection. Cell 2007;129(1):147–61.
17] Gao W,  Yu Y, Cao H, Shen H, Li X, Pan S, et al. Deregulated expression of
miR-21, miR-143 and miR-181a in non small cell lung cancer is related to
clinicopathologic characteristics or patient prognosis. Biomed Pharmacother
2010;64(6):399–408.
18] Taylor MA, Sossey-Alaoui K, Thompson CL, Danielpour D, Schiemann WP.  TGF-
  upregulates miR-181a expression to promote breast cancer metastasis. J Clin
Invest 2013;123(1):150–63.
19] Meng F, Glaser SS, Francis H, DeMorrow S, Han Y, Passarini JD, et al. Functional
analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol
Med  2012;16(1):160–73.
20] Zhang X, Nie Y, Du Y, Cao J, Shen B, Li Y. MicroRNA-181a promotes gas-
tric  cancer by negatively regulating tumor suppressor KLF6. Tumour Biol
2012;33(5):1589–97.
21] Wei  Z, Cui L, Mei  Z, Liu M,  Zhang D. miR-181a mediates metabolic shift in colon
cancer cells via the PTEN/AKT pathway. FEBS Lett 2014;588(9):1773–9.
22] Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu Z, et al. hsa-mir-181a and hsa-
mir-181b function as tumor suppressors in human glioma cells. Brain Res
2008;1236:185–93.
23] Shin KH, Bae SD, Hong HS, Kim RH, Kang MK,  Park NH. miR-181a shows tumor
suppressive effect against oral squamous cell carcinoma cells by downregulat-
ing K-ras. Biochem Biophys Res Commun 2011;404(4):896–902.
24] Sukhatme VP, Kartha S, Toback FG, Taub R, Hoover RG, Tsai-Morris CH. A novel
early growth response gene rapidly induced by ﬁbroblast, epithelial cell and
lymphocyte mitogens. Oncogene Res 1987;1(4):343–55.
25] Zheng L, Pu J, Jiang G, Weng M,  He J, Mei  H,  et al. Abnormal expression of
early growth response 1 in gastric cancer: association with tumor invasion,
metastasis and heparanase transcription. Pathol Int 2010 Apr;60(4):268–77.
26] Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson ED,  Mercola D.
Egr1 promotes growth and survival of prostate cancer cells Identiﬁcation of
novel Egr1 target genes. J Biol Chem 2003;278(14):11802–10.
27] Ferraro B, Bepler G, Sharma S, Cantor A, Haura EB. EGR1 predicts PTEN
and survival in patients with non-small-cell lung cancer. J Clin Oncol
2005;23(9):1921–6.
28] Liu J, Liu YG, Huang R, Yao C, Li S, Yang W,  et al. Concurrent down-regulation
of  Egr-1 and gelsolin in the majority of human breast cancer cells. Cancer
Genomics Proteomics 2007;4(6):377–85.
29] Gibbs JD, Liebermann DA, Hoffman B. Egr-1 abrogates the E2F-1 block
in  terminal myeloid differentiation and suppresses leukemia. Oncogene
2008;27(1):98–106.
30] Fulci V, Colombo T, Chiaretti S, Messina M,  Citarella F, Tavolaro S, et al. Char-
acterization of B- and T-lineage acute lymphoblastic leukemia by integrated
analysis of MicroRNA and mRNA expression proﬁles. Genes Chrom Cancer
2009;48(12):1069–82.
31] Raymond CK, Roberts BS, Garrett-Engele P, Lim LP, Johnson JM. Simple, quan-
titative primer-extension PCR assay for direct monitoring of microRNAs and
short-interfering RNAs. RNA 2005;11(11):1737–44.
32] Fulci V, Chiaretti S, Goldoni M,  Azzalin G, Carucci N, Tavolaro S, et al. Quanti-
tative technologies establish a novel microRNA proﬁle of chronic lymphocytic
leukemia. Blood 2007;109(11):4944–51.
33] Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor
Egr1 is a direct regulator of multiple tumor suppressors including TGF1, PTEN,
p53 and Fibronectin,. Cancer Gene Ther 2006;13(2):115–24.
34] Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor
suppressor? Cancer Metastasis Rev 2009;28(3–4):369–78.
35] Liu C, Adamson E, Mercola D. Transcription factor EGR-1 suppresses the growth
and transformation of human HT-1080 ﬁbrosarcoma cells by induction of trans-
forming growth factor beta 1. Proc Natl Acad Sci USA 1996;93:11831–6.
36] Huang RP, Fan Y, deBelle I, Ni Z, Matheny W,  Adamson ED. Egr-1 inhibits
apoptosis during the UV response: correlation of cell survival with Egr-1 phos-
phorylation. Cell Death Differ 1998;5:96–106.
37] de Belle I, Huang RP, Fan Y, Liu C, Mercola D, Adamson ED. p53 and Egr-1
additively suppress transformed growth in HT1080 cells but Egr-1 counteracts
p53-dependent apoptosis. Oncogene 1999;18:3633–42.
38] Krones-Herzig A, Eileen A, Dan M.  Early growth response 1 protein, a novel
upstream gatekeeper of the p53 tumor suppressor, controls replicative senes-
cence. Proc Natl Acad Sci USA 2003;100:3233–8.
39] Krones-Herzig A, Mittal S, Kelly Y, Hongyan L, Chris E, Rafael U,  et al. Early
growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation
of p53. Cancer Res 2005;65(12):5133–43.
40] Pignatelli M,  Luna-Medina R, Pérez-Rendón A, Santos A, Perez-Castillo A. The
transcription factor early growth response factor-1 (EGR-1) promotes apopto-
sis of neuroblastoma cells. Biochem J 2003;373:739–46.
